Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on April 16, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). Authorized common shares doubled from 200,000,000 to 400,000,000.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Authorized common shares doubled from 200,000,000 to 400,000,000
- Shareholder-approved amendment increases potential equity-financing capacity
- Expanded authorization may enable acquisitions, compensation, or strategic transactions
- Potential dilution risk for existing shareholders if new shares are issued
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 2026 meeting achieved quorum with 88,270,365 shares represented, or 67.8% of voting shares
- All nine director nominees elected, with 44,722,328–47,577,875 votes for each nominee
- Ernst & Young appointment ratified for fiscal 2026, with 84,959,584 votes for
- Authorized common shares doubled from 200 million to 400 million, enabling greater financing and dilution capacity
- 2019 ESPP reserve increased from 403,500 to 1,108,827 shares; say-on-pay approved with 39,928,184 votes for but 12,026,081 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.